Is Roche losing its oncologic steam?

Roche was the uncontested leader in oncologic drugs for nearly two decades. That’s changing, however, as its blockbusters give way to biosimilars, and more and more competitors enter the marketplace, the Wall Street Journal writes. Roche’s cancer drug sales were double those of its top competitor last year, but that lead is expected to shrink in the coming years.

The reason Roche had such a strong foothold in the cancer market is largely because of its partnership with Genentech, which it acquired in 2009. But revenues are projected to fall 12 percent over the next six years — while the overall cancer market nearly doubles.